Introduction Tuberculous meningitis accounts for 1–5% of tuberculosis cases. Diagnostic
delay contributes to poor outcomes. We evaluated the performance of the new Xpert MTB/RIF …

Background Identifying new antifungals for cryptococcal meningitis is a priority given the
inadequacy of current therapy. Sertraline has previously shown in vitro and in vivo activity …

Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM).
Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human …

Background Amphotericin B is the gold standard treatment for severe mycoses. A new orally
delivered, less-toxic formulation of amphotericin has been developed. Methods In our …

Background Increased antiretroviral therapy (ART) availability has been associated with
more patients developing cryptococcosis after ART initiation. Despite this changing …

Objectives Nodding syndrome (NS) is a poorly understood neurological disorder affecting
thousands of children in Africa. In March 2012, we introduced a treatment intervention that …

Background Cryptococcal meningitis can occur in persons with less-apparent immunosuppression.
We evaluated clinical characteristics and outcomes of persons with HIV-related …

Tuberculous meningitis (TBM) is the most lethal manifestation of tuberculosis and requires
rapid diagnosis and initiation of treatment to prevent death and serious neurological disability. …

Despite improvements in the antifungal regimens and the roll out of antiretroviral therapy (ART)
in sub-Saharan Africa, mortality due to cryptococcal meningitis remains high. Relapse of …

Quantitative cerebrospinal fluid (CSF) cultures provide a measure of disease severity in
cryptococcal meningitis. The fungal clearance rate by quantitative cultures has become a …